8-KRegulation FD

ABBOTT LABORATORIES 8-K Report, Regulation FD Disclosure (Mar 29, 2005)

Filed March 29, 2005For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on March 29, 2005, to disclose the issuance of a new patent for BIAXIN XL. This patent specifically covers the pharmacokinetic profile of the extended-release antibiotic, which is linked to improved clinical benefits such as maintaining consistent drug levels in the blood. The new patent strengthens the intellectual property surrounding BIAXIN XL, adding to existing patents for formulations and manufacturing processes. The patent protection for the formulation and pharmacokinetic aspects extends to 2017. This development is significant for investors as BIAXIN XL represents a key product for Abbott, accounting for nearly 70% of all BIAXIN prescriptions in the U.S. The extended-release formulation offers patients convenience with once-daily dosing and an improved adverse event profile, contributing to its market dominance over older formulations. The reinforced patent protection provides a longer period of market exclusivity, supporting continued revenue generation from this important therapeutic agent.

Key Highlights

  • 1Abbott Laboratories received a new U.S. patent for BIAXIN XL (extended-release clarithromycin) on March 29, 2005.
  • 2The patent protects the pharmacokinetic profile of BIAXIN XL, contributing to its clinical benefits like consistent blood drug levels.
  • 3This new patent enhances Abbott's intellectual property portfolio for BIAXIN XL, which already includes patents for formulations and manufacturing.
  • 4Formulation and pharmacokinetic patents for BIAXIN XL are now extended until 2017.
  • 5BIAXIN XL is a once-daily antibiotic for common respiratory tract infections.
  • 6BIAXIN XL accounts for nearly 70% of all BIAXIN prescriptions in the U.S.
  • 7The patent strengthens market exclusivity for a significant Abbott product.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce that Abbott Laboratories has been issued a new patent for its extended-release antibiotic, BIAXIN XL. This patent specifically covers the drug's pharmacokinetic profile.

The new patent strengthens Abbott's intellectual property protection for BIAXIN XL, extending patent coverage for its formulation and pharmacokinetic properties until 2017. This enhances the drug's market exclusivity and supports its continued revenue generation.

BIAXIN XL is a significant product for Abbott, as it accounts for nearly 70% of all BIAXIN prescriptions in the U.S. The extended-release formulation offers patient benefits like convenient once-daily dosing and an improved adverse event profile, making it the preferred version of the drug.

This filing is a disclosure of patent protection and does not directly impact the current availability or price. However, the strengthened patent protection implies continued market exclusivity for Abbott, which typically supports stable pricing and availability of the branded product.